We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
 Nuevolution Announces New Research Collaboration with Big Pharma
News

Nuevolution Announces New Research Collaboration with Big Pharma

 Nuevolution Announces New Research Collaboration with Big Pharma
News

Nuevolution Announces New Research Collaboration with Big Pharma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of " Nuevolution Announces New Research Collaboration with Big Pharma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nuevolution A/S has announced that it has entered into a drug discovery collaboration with Novartis.

During the collaboration, Nuevolution will apply its proprietary Chemetics® drug discovery technology to identify novel small molecule leads against drug targets of interest to Novartis. The Chemetics® platform uses DNA labeling to allow fragment-based drug screening at an unprecedented scale.

Nuevolution will screen its multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis and screening of target focused Chemetics® follow-up libraries, the parties will also work together to perform hit-to-lead optimization.

Under the terms of the agreement, Novartis will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market.

In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products. Further financial details were not disclosed.

“We are delighted that Novartis has elected to enter this collaboration with Nuevolution” said Alex Gouliaev, CEO of Nuevolution A/S, and continued: “We look forward to an exciting and fruitful outcome of the collaboration.”
Advertisement